“…However, there are no reports on the effects of different functionalized AuNPs on deubiquitinating enzymes (DUBs) and their utility in understanding anticancer pathways. DUBs are an important group of enzymes that play a significant role in cancer pathogenesis, development, and proliferation by removing attached ubiquitin from the substrate. , They are classified into ubiquitin c-terminal hydrolases (UCHs), ubiquitin specific proteases (USPs), ovarian tumor proteases (OTUs), machado Joephin domain proteases (MJDs), monocyte chemotactic protein induced proteins (MCPIPs), and JAB1/MPN/Mov34 metalloenzyme (JAMM). − Among these DUBs, USPs, and UCHs are the most well-studied as they are highly overexpressed in human cancers, suggestive of their roles in tumor progression. , It has been found that cell survival in liver, breast, and colorectal cancers was promoted by an elevated level of USPs through simultaneously inhibiting apoptotic proteins and promoting tumor metastasis. , UCHL-1 overexpression has also been positively correlated with development, invasiveness, and chemotherapy resistance in some cancers including pancreatic, myeloma, neuroblastoma, nonsmall cell lung cancer (NSCLC), prostate, and lymphoma. , The overarching aim of this study is to understand the effects of tannate, citrate, and PVP functionalized 5 nm AuNPs on DUBs with a particular focus on USPs and UCHL-1 in A549 cells proliferation and toxicity. The study further hypothesized if the inhibition of these DUBs could lead to the downregulation of PI3K/AKT/mTOR, Wnt signaling pathway related proteins, and activation of mitochondrial apoptosis.…”